Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

YSCH-01 for Recurrent or Progressive Glioblastoma

13 de novembro de 2026 atualizado por: Shanghai Yuansong Biotechnology Co., Ltd.

A Single-Arm, Open-Label, Dose-Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of YSCH-01 in Subjects With Recurrent or Progressive Glioblastoma

This is an open-label dose-escalation and dose-expansion study that plans to enroll 16 to 32 adult participants with recurrent or progressive glioblastoma. Participants will be assigned to different dose groups. This study consists of two parts, namely the dose escalation stage and the dose expansion stage. The study aims to determine the safety and tolerability of the oncolytic adenovirus YSCH-01 in adult participants with recurrent or progressive glioblastoma.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

32

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Shanghai, China, 200040
        • Huashan Hospital
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Subjects who are willing to sign the informed consent form (ICF), able to understand the study, and willing to follow the protocol and complete all the study procedures;

  2. Male or female aged ≥ 18 and ≤ 75 years;

  3. Disease status: Subjects with an initial glioblastoma histopathologically confirmed in accordance with the 2021 WHO Classification of Tumors of the Central Nervous System, who have developed disease recurrence or progression following standard of care. The standard of care consists of surgical resection, chemotherapy and/or radiotherapy. For subjects with known specific molecular alterations (e.g., NTRK fusions), prior standard targeted therapy recommended by the latest local guidelines is required, except for subjects for whom the investigator judges standard of care to be inapplicable, of limited benefit, or intolerable; the rationale for intolerance shall be documented.

  4. Patients with at least one measurable lesion (≥10 mm in both perpendicular diameters as per RANO 2.0 criteria) within 4 weeks before YSCH-01 treatment;

  5. Subjects with a karnofsky performance status (KPS) score of ≥70 and the expected survival period is ≥ 3 months;

  6. Subjects with adequate organ and hematopoietic function:

    Hematological function: absolute neutrophil count (ANC) ≥1.0×10⁹/L, hemoglobin (HGB) ≥90 g/L, platelet count (PLT#) ≥100×10⁹/L. No blood transfusion, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human erythropoietin, recombinant human thrombopoietin, platelet receptor agonists, recombinant human interleukin-11, or other supportive treatments within 14 days prior to screening; Liver function: total bilirubin (TBIL) ≤2×ULN, except for subjects with Gilbert's syndrome; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN (≤5×ULN in the presence of liver metastases); Renal function: serum creatinine (Cr) ≤1.5×ULN; Coagulation function: in the absence of anticoagulant therapy, prothrombin time (PT), activated partial thromboplastin time (APTT), or international normalized ratio (INR) ≤1.5×ULN

  7. Male subjects of reproductive potential and female subjects of childbearing potential must agree to use reliable contraceptive methods (hormonal contraception, barrier methods, or abstinence) during the study and for at least 6 months after the last dose of YSCH-01; female subjects of childbearing potential must have a negative blood or urine pregnancy test within 7 days prior to enrollment.

Exclusion Criteria:

  1. Subjects with a known severe allergy to any component of the investigational drug, Ommaya reservoir, or other oncolytic virus therapies;

  2. Pregnant or breast-feeding women;

  3. Subjects with positive results for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb), and a hepatitis B virus deoxyribonucleic acid (HBV-DNA) level higher than the lower limit of detection; subjects with a positive result for hepatitis C virus (HCV) antibody and a hepatitis C virus ribonucleic acid (HCV-RNA) level higher than the lower limit of detection; subjects with a positive result for human immunodeficiency virus (HIV) antibody;

  4. Subjects who received chemotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor drugs within 4 weeks prior to the first dose; Chinese herbal medicines or Chinese patent medicines with anti-tumor indications within 2 weeks; Subjects who received radiotherapy within 4 weeks days prior to the first dose;

  5. Subjects with known or suspected active autoimmune diseases, including but not limited to Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.;

  6. Subjects who require systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive medication within 14 days prior to the first dose or during the study, with the following exceptions:

    Adrenaline replacement steroids (prednisone ≤10 mg/day or equivalent); Topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids; Prophylactic short-term (≤7 days) use of corticosteroids (e.g., allergy to contrast media) or for the treatment of non-autoimmune diseases (e.g., delayed hypersensitivity reactions caused by contact allergens).

  7. Subjects with tumor lesions in critical anatomic areas (e.g., ventricular invasion or proximity to the brainstem and spinal cord, or the posterior fossa);

  8. Subjects with clinically significant increased intracranial pressure (e.g., impending brain herniation or requirement for immediate palliative treatment) or uncontrolled seizures;

  9. Subjects with poorly controlled mental disorders, or who, in the investigator's opinion, have a medical history or mental state that may increase the risks associated with study participation or investigational drug administration, or that may interfere with the study results;

  10. Subjects with toxicity and side effects caused by previous treatment that have not recovered to Grade ≤1 (per CTCAE V6.0); except for alopecia and other tolerable events judged by the investigator;

  11. Presence of cardiovascular disease or conditions including any of the following:

    There are severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, etc.; At rest, the average QTcF obtained from 3 12-lead electrocardiogram examinations is greater than 450ms; Within 6 months before the first administration, acute coronary syndrome, congestive heart failure, stroke or other grade 3 or above cardiovascular events occurred; The New York Heart Association (NYHA) cardiac function classification is ≥ II grade or the left ventricular ejection fraction (LVEF) is less than 50%; Any factors that increase the risk of QTc prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, long QT syndrome family history or a first-degree relative having sudden death before the age of 40 that cannot be explained, or using any known drugs that can prolong the QT interval.

  12. Subjects who have participated in other interventional clinical studies within 1 month prior to study treatment;

  13. Subjects who have previously received oncolytic virus therapy ;

  14. Subjects with any contraindication for undergoing an Ommaya reservoir implantation procedure;

  15. Subjects with any contraindication to magnetic resonance imaging (MRI), including pacemakers, epicardial pacing wires, infusion pumps, surgical and/or aneurysm clips, shrapnel, metal prostheses, or implants with potential magnetic properties;

  16. Subjects with any serious or poorly controlled disease that, in the investigator's opinion, may increase the risks associated with study participation, investigational drug administration, or affect the subject's ability to receive the investigational drug, including but not limited to cardiovascular and cerebrovascular diseases, renal insufficiency, pulmonary embolism, coagulopathy, conditions requiring long-term anticoagulant therapy, active infection, and uncontrollable infection requiring long-term systemic treatment;

  17. Subjects who have alcoholism, drug use or drug abuse;

  18. Subjects with other malignant neoplasms within the past 3 years or currently, except for non-melanoma skin cancer and carcinoma in situ (e.g., cervical, bladder, and breast carcinoma in situ);

  19. Subjects who receive live vaccines within 4 weeks prior to the first dose or planned during the study period;

  20. Subjects with other conditions that, in the investigator's opinion, render the subject unsuitable for enrollment..

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Dose Escalation

Participants will receive the investigational product during the dose-escalation phase. The low-dose Dose cohort will enroll 3 participants initially. If no dose-limiting toxicities (DLTs) are observed in these 3 participants during the protocol-defined DLT observation period, enrollment at the higher dose level may proceed in accordance with the protocol-defined dose-escalation criteria. Safety and tolerability will be evaluated to determine the dose for further investigation.

After being enrolled, the participants underwent tumor biopsy/ resection and then an Ommaya reservoir was implanted into the tumor. The participants would receive single-agent treatment with YSCH-01 every 3 weeks. YSCH-01 was administered within the tumor through the implanted Ommaya reservoir.

Outros nomes:
  • Recombinant L-IFN adenovirus injection
Experimental: Dose Expansion

Participants will receive the trial product at the selected dose level based on the results of the dose escalation phase. The dose expansion phase will further assess the safety and tolerability of the selected dose, and evaluate its initial anti-tumor activity under the same overall disease population and the same primary inclusion criteria.

After being enrolled, the participants underwent tumor biopsy/ resection and then an Ommaya reservoir was implanted into the tumor. The participants would receive single-agent treatment with YSCH-01 every 3 weeks. YSCH-01 was administered within the tumor through the implanted Ommaya reservoir.

Outros nomes:
  • Recombinant L-IFN adenovirus injection

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence of Dose Limiting Toxicities (DLT)
Prazo: 21 days after the first dose and 21 days after the second dose

During the DLT observation period following the administration of YSCH-01, the incidence of DLTs will be evaluated. The occurrence of DLTs will be determined according to the criteria specified in the protocol

21 days after the first dose and 21 days after the second dose
Safety and tolerability assessed by Adverse Events (AEs)
Prazo: From first dose up to 28 days after last dose

The incidence, severity, seriousness, and relationship to YSCH-01 of adverse events (AEs) will be assessed. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) 2018 consensus grading criteria. All other AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 6.0. Adverse events will be characterized by type, severity grade, seriousness, relationship to the investigational product, and outcome

From first dose up to 28 days after last dose

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Overall Survival (OS)
Prazo: From the first dose to 1 year post first dose

The time from the first dose to death from any cause

From the first dose to 1 year post first dose
Progression-free survival (PFS)
Prazo: From the first dose to the date of documented disease progression or death from any cause, whichever occurs first, assessed for up to 6 months

To evaluate progression-free survival per Response Assessment in Neuro-Oncology (RANO) , version 2.0 criteria

From the first dose to the date of documented disease progression or death from any cause, whichever occurs first, assessed for up to 6 months
Viral Biodistribution of YSCH-01 in Blood
Prazo: Baseline (within 2 hours before the first dose); 2, 4, 6, 24, 72, and 168 hours post first dose; predose and 2, 6, and 24 hours post the second to fifth dose; end of treatment (up to 1 year); 28 days after the last dose

Viral DNA levels of YSCH-01 in blood will be measured by quantitative real-time polymerase chain reaction (qPCR) to evaluate the biodistribution of YSCH-01

Unit of Measure: Copies/μg DNA

Baseline (within 2 hours before the first dose); 2, 4, 6, 24, 72, and 168 hours post first dose; predose and 2, 6, and 24 hours post the second to fifth dose; end of treatment (up to 1 year); 28 days after the last dose
Viral DNA Shedding of YSCH-01 in Feces
Prazo: Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose

Viral DNA levels of YSCH-01 in feces samples will be measured by quantitative real-time polymerase chain reaction (qPCR) to evaluate fecal viral DNA shedding following treatment

Unit of Measure: Copies/μg DNA

Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose
Viral DNA Shedding of YSCH-01 in Urine
Prazo: Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose

Viral DNA levels of YSCH-01 in urine samples will be measured by quantitative real-time polymerase chain reaction (qPCR) to evaluate fecal viral DNA shedding following treatment

Unit of Measure: Copies/reaction

Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose
Viral DNA Shedding of YSCH-01 in Nasopharyngeal Fluid
Prazo: Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose

Viral DNA levels of YSCH-01 in nasopharyngeal fluid samples will be measured by quantitative real-time polymerase chain reaction (qPCR) to evaluate fecal viral DNA shedding following treatment

Unit of Measure: Copies/reaction

Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose
Pharmacodynamic (PD): Serum IL-2 concentration
Prazo: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

Serum IL-2 concentrations will be measured using the MSD assay

Unit of Measure: pg/mL

Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
PD: Serum IL-6 Concentration
Prazo: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

Serum IL-6 concentrations will be measured using the MSD assay

Unit of Measure: pg/mL

Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
PD: Serum IL-8 Concentration
Prazo: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

Serum IL-8 concentrations will be measured using the MSD assay

Unit of Measure: pg/mL

Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
PD: Serum IL-10 Concentration
Prazo: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

Serum IL-10 concentrations will be measured using the MSD assay

Unit of Measure: pg/mL

Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
PD: Serum IL-12 concentration
Prazo: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

Serum IL-12 concentrations will be measured using the MSD assay

Unit of Measure: pg/mL

Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
PD: Serum TNF-α concentration
Prazo: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

Serum TNF-α concentrations will be measured using the MSD assay

Unit of Measure: pg/mL

Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
PD: Serum IFN-γ concentration
Prazo: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

Serum IFN-γ concentrations will be measured using the MSD assay

Unit of Measure: pg/mL

Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)
Anti-drug antibody (ADA) of adenovirus
Prazo: Pre-2 hours of each dose; at the end of treatment (up to 1 year)

Serum levels of anti-YSCH-01 antibodies will be measured by enzyme-linked immunosorbent assay (ELISA) before and after treatment. Antibody levels will be reported in ng/mL

Unit of Measure: ng/mL

Pre-2 hours of each dose; at the end of treatment (up to 1 year)

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Changes of immune cell infiltration and the tumor microenvironment in paired tumor tissue samples
Prazo: At baseline surgery and at post-treatment repeat surgery, when available, within 1 year after the first dose

Paired tumor tissue samples collected at baseline and after treatment from participants undergoing repeat surgery will be analyzed to characterize changes in immune cell infiltration, immune cell populations, tumor immune microenvironment (TME) remodeling, and stromal composition following treatment

At baseline surgery and at post-treatment repeat surgery, when available, within 1 year after the first dose
Cell-Free DNA (cfDNA) Levels in Cerebrospinal Fluid and Peripheral Blood
Prazo: At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available

Cell-free DNA (cfDNA) levels in cerebrospinal fluid (CSF), when available, and peripheral blood will be assessed using next-generation sequencing (NGS) or other validated molecular assays to explore their associations with treatment response

At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available
Cytokine Profiles in Cerebrospinal Fluid
Prazo: At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available

Concentrations of IL-2, IL-6, IL-8, IL-10, IL-12, TNF-α, and IFN-γ in cerebrospinal fluid (CSF) will be measured using the MSD assay, consistent with the peripheral blood pharmacodynamic (PD) cytokine assessments. Each cytokine will be reported separately in pg/mL to explore treatment-related changes and their associations with treatment response

Unit of Measure: pg/mL

At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available
Absolute Counts of Immune Cell Populations in Cerebrospinal Fluid and Peripheral Blood
Prazo: At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available

Absolute counts of T cells, B cells, NK cells, and myeloid cells in cerebrospinal fluid (CSF) and peripheral blood will be characterized using flow cytometry. The absolute counts of each immune cell population will be reported separately in cells/mL to explore treatment-related changes and their associations with treatment response

Unit of Measure: cells/mL

At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

10 de novembro de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2028

Conclusão do estudo (Estimado)

1 de dezembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

1 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de novembro de 2026

Primeira postagem (Real)

19 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • YSCH-01-CN002
  • CTR20263831 (Identificador de registro: China Drug Trials Registry (CTR))
  • CXSL2501156 (Outro identificador: CDE, NMPA China)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever